Live Breaking News & Updates on Field Biopharmaceuticals

Stay updated with breaking news from Field biopharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024 ASCO Annual Meeting

HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024 ASCO Annual Meeting
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United States , Yuhong Xu , American Society Of Clinical Oncology , Field Biopharmaceuticals , American Society , Clinical Oncology ,

HighField Biopharmaceuticals HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe, Well-Tolerated and Efficacious in Solid Tumors

HANGZHOU, China (BUSINESS WIRE) Jan 8, 2024 ....

Dan Eramian , Donald Wyatt , Yuhong Xu , Business Development Contact , Opus Biotech Communications , Field Biopharmaceuticals , Media Contact , Development Contact , Business Wire , Nation World ,

HighField Biopharmaceuticals Doses First Patient in Phase 1 Trial of HFK1, a Unique Immunoliposome, for Treatment of HER2 low and HER2+ Cancers

HighField Biopharmaceuticals Doses First Patient in Phase 1 Trial of HFK1, a Unique Immunoliposome, for Treatment of HER2 low and HER2+ Cancers
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United States , Yuhong Xu , Donald Wyatt , Mary Crowley Cancer Research , Product Service , Field Biopharmaceuticals Doses First Patient , Unique Immunoliposome , Field Biopharmaceuticals , Chief Medical , Executive Medical Director ,

HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers

HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Dan Eramian , Yuhong Xu , Donald Wyatt , Highfield Bio , Business Development Contact , Opus Biotech Communications , Drug Administration , Field Biopharmaceuticals , Investigational New Drug , Field Bio , Development Contact ,

HighField Biopharmaceuticals' HF1K16, a New Immuno-Oncology Drug, Shows Promise in Patients with Refractory Glioblastoma | Illinois

HANGZHOU, China (BUSINESS WIRE) May 31, 2023 ....

Mccormick Place , United States , Highfield Bio , Donald Wyatt , Yuhong Xu , Dan Eramian , Business Development Contact , American Society Of Clinical Oncology , Opus Biotech Communications , Field Biopharmaceuticals , American Society , Clinical Oncology , Myeloid Derived Suppressor Cells , Field Bio , Media Contact , Development Contact , Business Wire ,